NASDAQ · DMRA
Damora Therapeutics, Inc.
$22.01+$0.40 (+1.85%)
Damora Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.58% below the high.
Loading market information…
NASDAQ · RNAZ · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
TransCode Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.27% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
TransCode Therapeutics, Inc.’s next earnings report is currently expected on Nov 18, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow TransCode Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00-100.0% vs estimate |
| Q3 2024 | Nov 14, 2024 | -$147.91+67.33% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$22.01+$0.40 (+1.85%)
Damora Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.58% below the high.
$6.36-$0.22 (-3.34%)
Bolt Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.25% below the high.
$0.86-$0.05 (-5.91%)
Phio Pharmaceuticals Corp.’s quoted price sits in the lower half of its reported 52-week range, 79.41% below the high.
$0.98-$0.04 (-3.91%)
IN8bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.1% below the high.
$1.76-$0.60 (-25.42%)
Kiora Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.52% below the high.
$0.49-$0.04 (-8.22%)
Aprea Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.87% below the high.
$1.07$0.00 (0.0%)
Acurx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.81% below the high.
$1.36+$0.06 (+4.62%)
Aptevo Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.22% below the high.
